SKN | Can Novo Nordisk Strengthen Its Weight-Loss Lead After Europe Approves Oral Wegovy?
Stock Analysis Shares of Novo Nordisk moved higher after the European Commission approved the company’s once-daily oral version of Wegovy for adults living with obesity or overweight conditions accompanied by at least one weight-related illness. The decision marks an important milestone for the Danish pharmaceutical company, making Wegovy the first oral GLP-1 therapy authorized for weight management […]